Liraglutide Plus Metformin Boosts Weight Loss in Obese PCOS Women
Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary Syndrome
Background
Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder affecting women, characterized by hormonal imbalances, insulin resistance, and often obesity. Metformin is a first-line treatment for PCOS, improving insulin sensitivity and menstrual regularity, but its impact on weight loss can be modest. This study aimed to determine if adding liraglutide, a GLP-1 receptor agonist, to metformin therapy could provide superior weight reduction and metabolic improvements in obese women with PCOS.
Study Design
Population
Obese women with Polycystic Ovary Syndrome (PCOS) and insulin resistance.
Intervention
Liraglutide added to metformin therapy.
Comparator
Metformin monotherapy.
Outcome
Superior weight reduction and metabolic improvements.
